ArriVent Dosed First Patient in ARR-002 Cancer Trial
The Phase 1 trial evaluates the dual-target antibody-drug conjugate in patients with advanced ovarian or endometrial cancer.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient health when developing novel cancer treatments?
ArriVent BioPharma has dosed the first patient in a U.S.-based Phase 1 clinical trial for its lead candidate, ARR-002. The study assesses the safety, tolerability, and efficacy of this dual-target antibody-drug conjugate for treating metastatic or advanced gynecological cancers.
Why it matters
ARR-002 is designed to target MUC16 and NaPi2b, two proteins often over-expressed in ovarian and endometrial tumors. This dual-targeting approach aims to address the limitations of conventional antibody-drug conjugates when treating tumors that exhibit heterogeneous target expression.
The ARR-002 conjugate utilizes site-specific conjugation to vcMMAE with a drug-to-antibody ratio of 4. Researchers are evaluating its performance in patients with advanced or metastatic ovarian or endometrial cancer.
The players
ArriVent BioPharma
A clinical-stage biopharmaceutical company headquartered in Newtown Square, Pennsylvania, that focuses on discovering and developing transformative cancer treatments.
Shanghai Allist Pharmaceuticals
A Chinese biopharmaceutical company that holds the licensing rights for the development and commercialization of ARR-002 in Greater China.
The details
The experimental therapy combines targeting for MUC16 and NaPi2b to better penetrate solid tumors. By utilizing a site-specific conjugation method, the drug aims to provide a more stable and targeted payload compared to single-target alternatives.
Timeline
August 2026: ArriVent finalized a licensing deal with Shanghai Allist Pharmaceuticals.
October 12, 2026: The first patient was officially dosed in the Phase 1 trial.
The Big Picture
The development of the MUC16/NaPi2b dual-target antibody-drug conjugate platform represents a shift away from single-target therapies. The initiation of the ARR-002 trial marks the first human-testing milestone for this specific dual-target technology.
This trial offers a new clinical investigation route for patients with metastatic or advanced ovarian and endometrial cancers who have limited treatment options. Participants in this Phase 1 study will be closely monitored to determine the safety and tolerability of the new therapy.
The takeaway
Dual-target therapies represent an emerging strategy to overcome the resistance challenges common in solid tumor treatment. Patients interested in experimental treatments should consult their oncologists about eligibility for clinical trials involving antibody-drug conjugates.
Further reading
For more information on ongoing clinical research, visit the Cancer section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health when developing novel cancer treatments?
